Phase II Trial of Atezolizumab and Tiragolumab for Patients With Detectable Circulating Tumor DNA After Definitive Treatment for HPV-positive Squamous Cell Carcinoma
Latest Information Update: 16 Jan 2025
Price :
$35 *
At a glance
- Drugs Atezolizumab (Primary) ; Tiragolumab (Primary)
- Indications Anal cancer; Carcinoma; Squamous cell cancer
- Focus Adverse reactions
- 16 Jan 2025 New trial record